## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)	
Jon SCHNECK and Mathias OELKE	)	Group Art No. TBA
Serial No: TBA	)	Examiner: TBA
Filed: even herewith	)	Docket No. 001107.00355

For: REAGENTS AND METHODS FOR ENGAGING UNIQUE

**CLONOTYPIC LYMPHOCYTE RECEPTORS** 

## INFORMATION DISCLOSURE STATEMENT

MAIL STOP PATENT APPLICATION Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, accompanying this paper is a Form PTO-1449 listing documents for consideration in the application referenced above. Copies of the listed documents are enclosed.

Applicants wish to call the Examiner's attention to Serial No. 09/642,660 filed August 22, 2000, which is listed on the Form PTO-1449. A copy of this application is not enclosed, because its disclosure is identical to that of issued patent U.S. Patent 6,268,411, and a copy of that patent is enclosed. The claims pending in Serial No. 09/642,660 are currently under final rejection. A petition to expunge any copies of Serial No. 09/642,660 and its related prosecution accompanies this Information Disclosure Statement.

Applicants also wish to call the Examiner's attention to US 2002/0006903, which was published on January 17, 2002. The claims pending in this application stand rejected.

Respectfully submitted,

BANNER & WITCOFF, LTD.

Date: July 14, 2003

By:

Lisa M. Hemmendinger Registration No. 42,653

1001 G. Street, N.W. Eleventh Floor Washington, D.C. 20001 (202) 824-3000 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known INFORMATION DISCLOSURE **Application Number** tba Filing Date July 14, 2003 STATEMENT BY APPLICANT First Named Inventor Schneck Group Art Unit tba (use as many sheets as necessary) **Examiner Name** tba Sheet of 001107.00355 Attorney Docket Number

U.S. PATENT DOCUMENTS					
	Cite		Publication Date	Name of Patentee or Applicant	Pages, Columns, Lines, Where Relevar Passages or Relevant Figures Appear
	No.1		MM-DD-YYYY	of Cited Document	
		5,583,031	December 10, 1996	Stern	
		6,015,884	January 18, 2000	Schneck et al.	
•		6,140,113	October 31, 2000	Schneck et al.	
		6,448,071	September 10, 2002	Schneck et al.	
		6,458,354	October 1, 2002	Schneck et al.	
		6,268,411	July 31, 2001	Schneck et al.	
		US 2002/0119121	August 29, 2002	Vitiello et al.	
		US 2002/0122818	September 5, 2002	Albani	
		US 2003/0077248	April 24, 2003	Moriarty et al.	
		Serial No. 09/642,660	unpublished	Schneck et al.	
		2002/0006903	January 17, 2002	Schneck et al.	

		FORE	EIGN PATENT DOCU	MENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document  Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>3</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵	
1		WO 01/94944	December 13, 2001	Memorial Sloan- Kettering Cancer Center			
	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>		
		Goldberg et al., "In vivo Augmentation of Tumor-Specific CTL Responses by Class I/Peptide Antigen Complexes on Microspheres (Large Multivalent Immunogen)," J. Immunol. 170, 228-35, 2003					
		Latouche & Sadelain, "Induction of human cytotoxic T lymphocytes by artifical antigen-presenting cells," Nature Biotechnol. 18, 405-09, April 2000					
		Levine et al., "Effects of CD28 Costimulation on Long-Term Proliferation of CD4+ T cells in the Absence of Exogenous Feeder Cells," J. Immunol. 159, 5921-30, 1997					
	Maus et al., "Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB," Nature Biotechnol. 20, 143-48, February 2002						
		Maus et al., "HLA tetramer-based artificial antigen-presenting cells for stimulation of CD4+ T cells," Clin. Immunol. 106, 16-22, 2003					

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.